News Article | May 19, 2017
May 19 is International Clinical Trials Day, a day which QPS Bio-Kinetic, an independent Phase 1 Clinical Research Organization, recognizes the contributions its clinical researchers have to medical progress. Springfield, MO, May 19, 2017 --( Kayce Morton, a principal investigator at the Springfield, Missouri facility, began her career in clinical research as a participant at QPS Bio-Kinetic in the late 90s, gaining employment there as a phlebotomist while attending college at Drury University. She continued her employment throughout her educational career serving as a clinical research technician while in medical school. Today, Morton works alongside many of the veteran researchers she first met as a participant. “It gives me peace to know many pharmaceutical companies are here to make a difference, not just to make money,” explains Morton. “They support research and seek FDA approval for drugs to help prove their worth.” Bourg shares his appreciation for Morton’s dedication to the organization, and adds, “I am grateful for the role each of us has in clinical research, and for our potential as an organization to significantly change lives.” In addition to her position as an investigator at QPS Bio-Kinetic, Morton is a practicing pediatric hospitalist and is involved in the community with various organizations. To raise awareness for Clinical Trials’ Day, QPS Bio-Kinetic recognizes Morton for her contribution and invites all of its employees to wear blue to work to help publicize the importance of clinical research. For more information about Clinical Trials Day, please visit the website at www.clinicaltrialsday.org Springfield, MO, May 19, 2017 --( PR.com )-- “It’s important we take the time to recognize, celebrate and thank the people who perform ethical and responsible clinical research,” said Brendon Bourg, QPS Bio-Kinetics’ Vice President.Kayce Morton, a principal investigator at the Springfield, Missouri facility, began her career in clinical research as a participant at QPS Bio-Kinetic in the late 90s, gaining employment there as a phlebotomist while attending college at Drury University.She continued her employment throughout her educational career serving as a clinical research technician while in medical school. Today, Morton works alongside many of the veteran researchers she first met as a participant.“It gives me peace to know many pharmaceutical companies are here to make a difference, not just to make money,” explains Morton. “They support research and seek FDA approval for drugs to help prove their worth.”Bourg shares his appreciation for Morton’s dedication to the organization, and adds, “I am grateful for the role each of us has in clinical research, and for our potential as an organization to significantly change lives.”In addition to her position as an investigator at QPS Bio-Kinetic, Morton is a practicing pediatric hospitalist and is involved in the community with various organizations.To raise awareness for Clinical Trials’ Day, QPS Bio-Kinetic recognizes Morton for her contribution and invites all of its employees to wear blue to work to help publicize the importance of clinical research. For more information about Clinical Trials Day, please visit the website at www.clinicaltrialsday.org Click here to view the list of recent Press Releases from QPS Bio-Kinetic
News Article | April 18, 2017
For a historic seventh consecutive year, Benchmark Research along with PMG Research Associates and Miami Research Associates, co-members in the VaxCorps vaccine consortium, were named one of the top two Clinical Research Sites or Network. Benchmark Research has been a top finalist since the inception of this category; winning the award four times previously, and first runner up the other three years. The only awards ceremony dedicated to the vaccine industry, the annual Vaccine Industry Excellence (ViE) Awards honor individuals, organizations and initiatives which have made significant contributions to the industry over the past 12 months. “We congratulate Brenda Atchison and AMR for their well-deserved win this year, and thank our partners in VaxCorps, PMG and QPS/MRA for working with Benchmark to become the unparalleled vaccine network in the world. We are also deeply grateful to have been in the top two sites/networks for seven consecutive years, and are proud that no other company has achieved these accolades in any other category. Finally, and most importantly, we are blessed by all the Benchmark Family employees who ultimately are responsible for this prestigious award," said Mark Lacy, CEO of Benchmark Research. Benchmark Research is a fully integrated network of multi-therapeutic research sites, spanning three states. With the innovative opening of three Urgent & Family Care Centers this past year, Benchmark Research is enhancing the company patient database, taking on a broader spectrum of indications and is bringing added value to patients and clients. Started in 1997, Benchmark Research continues to lead in the quest to provide excellence in the clinical research industry.
News Article | April 26, 2017
This report studies the global Hydrographic Acquisition Software market, analyzes and researches the Hydrographic Acquisition Software development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like Market segment by Type, Hydrographic Acquisition Software can be split into 32-bit Processor 64-bit Processor Market segment by Application, Hydrographic Acquisition Software can be split into Research Institute Enterprise Laboratory Other At any Query @ https://www.wiseguyreports.com/enquiry/1218952-global-hydrographic-acquisition-software-market-size-status-and-forecast-2022 Table of Contents Global Hydrographic Acquisition Software Market Size, Status and Forecast 2022 1 Industry Overview of Hydrographic Acquisition Software 1.1 Hydrographic Acquisition Software Market Overview 1.1.1 Hydrographic Acquisition Software Product Scope 1.1.2 Market Status and Outlook 1.2 Global Hydrographic Acquisition Software Market Size and Analysis by Regions 1.2.1 United States 1.2.2 EU 1.2.3 Japan 1.2.4 China 1.2.5 India 1.2.6 Southeast Asia 1.3 Hydrographic Acquisition Software Market by Type 1.3.1 32-bit Processor 1.3.2 64-bit Processor 1.4 Hydrographic Acquisition Software Market by End Users/Application 1.4.1 Research Institute 1.4.2 Enterprise 1.4.3 Laboratory 1.4.4 Other 2 Global Hydrographic Acquisition Software Competition Analysis by Players 2.1 Hydrographic Acquisition Software Market Size (Value) by Players (2016 and 2017) 2.2 Competitive Status and Trend 2.2.1 Market Concentration Rate 2.2.2 Product/Service Differences 2.2.3 New Entrants 2.2.4 The Technology Trends in Future 3 Company (Top Players) Profiles 3.1 Stema Systems 3.1.1 Company Profile 3.1.2 Main Business/Business Overview 3.1.3 Products, Services and Solutions 3.1.4 Hydrographic Acquisition Software Revenue (Value) (2012-2017) 3.1.5 Recent Developments 3.2 Teledyne Marine 3.2.1 Company Profile 3.2.2 Main Business/Business Overview 3.2.3 Products, Services and Solutions 3.2.4 Hydrographic Acquisition Software Revenue (Value) (2012-2017) 3.2.5 Recent Developments 3.3 QPS 3.3.1 Company Profile 3.3.2 Main Business/Business Overview 3.3.3 Products, Services and Solutions 3.3.4 Hydrographic Acquisition Software Revenue (Value) (2012-2017) 3.3.5 Recent Developments 3.4 Chesapeake Technology 3.4.1 Company Profile 3.4.2 Main Business/Business Overview 3.4.3 Products, Services and Solutions 3.4.4 Hydrographic Acquisition Software Revenue (Value) (2012-2017) 3.4.5 Recent Developments 3.5 Ifremer 3.5.1 Company Profile 3.5.2 Main Business/Business Overview 3.5.3 Products, Services and Solutions 3.5.4 Hydrographic Acquisition Software Revenue (Value) (2012-2017) 3.5.5 Recent Developments 3.6 CEE HydroSystems (HYPACK) 3.6.1 Company Profile 3.6.2 Main Business/Business Overview 3.6.3 Products, Services and Solutions 3.6.4 Hydrographic Acquisition Software Revenue (Value) (2012-2017) 3.6.5 Recent Developments 3.7 EIVA 3.7.1 Company Profile 3.7.2 Main Business/Business Overview 3.7.3 Products, Services and Solutions 3.7.4 Hydrographic Acquisition Software Revenue (Value) (2012-2017) 3.7.5 Recent Developments 4 Global Hydrographic Acquisition Software Market Size by Type and Application (2012-2017) 4.1 Global Hydrographic Acquisition Software Market Size by Type (2012-2017) 4.2 Global Hydrographic Acquisition Software Market Size by Application (2012-2017) 4.3 Potential Application of Hydrographic Acquisition Software in Future 4.4 Top Consumer/End Users of Hydrographic Acquisition Software For more information, please visit https://www.wiseguyreports.com/sample-request/1218952-global-hydrographic-acquisition-software-market-size-status-and-forecast-2022
News Article | December 20, 2016
NEW YORK, NY--(Marketwired - Dec 20, 2016) - Netmining, leading provider of programmatic data-driven targeting solutions and Grapeshot, a global technology company, providing tools to navigate advertising and marketing choice, announce a powerful new integration to transform key-word and multi-language enhanced targeting, leveraging premium data sets, across a global offering. The integration delivers a joint capability that allows marketers and their agencies to execute precision targeting of quality audiences at global scale. "We're very excited about adding Grapeshot's keyword level targeting to complement what we're already doing from an audience targeting standpoint," said Joe Lavan, Vice President of Data and Insights at Netmining. "I'm confident this partnership will continue to bear strong results for our advertisers as we move into 2017." A Closer Look at the Integration Netmining, known for its innovative, premium data solutions, now will leverage Grapeshot's proprietary keyword technology for real-time targeting enrichment, across multiple languages, allowing the company to expand their client campaign efforts globally. "Through Grapeshot's machine learning and information retrieval technology, Netmining can operate with greater scale and accuracy reaching high-value, engaged audiences. Netmining's clients will experience performance growth using our keyword signals, as they expand internationally across multiple languages," said John Snyder, Co-Founder and CEO at Grapeshot. In addition to driving efficient and accurate targeted reach for performance campaigns, Grapeshot's custom targeting and brand safety will serve as a pivotal asset in Netmining's continued success across branding initiatives. Grapeshot's highly customizable keyword technology will allow Netmining to overlay hyper-relevant targeting with their proprietary audience targeting solutions, furthering content and brand alignment capabilities. About Netmining Netmining provides intelligent audience targeting, powered by data and shaped by the best analytical minds in the business. We believe your marketing should be driven by human insights using data as a tool, not the other way around. This approach creates a deeper understanding of your brand. With the challenge of fragmented consumer media habits, Netmining's cross-device targeting and attribution allows marketers to find their high-value consumers wherever they are across all screens of engagement. The result is your most important audience, delivered. For more information, please visit netmining.com or follow us on Twitter @netmining. Netmining is a member of the Interactive Advertising Bureau (IAB), the Network Advertising Initiative (NAI) and the Digital Advertising Alliance (DAA). About Grapeshot Grapeshot is a global privately-owned technology company that deploys machine learning to unlock the value from data. Using a page crawling algorithm, Grapeshot profiles data on behalf of marketers and developers, as well as agencies and publishers. The core WordRank technology offers a fully customizable, transparent and scalable solution, giving clients simple, integrated control. A first-class solution that operates at scale, processing large amounts of data efficiently. Grapeshot receives requests for 7T classifications per month, 3.5m QPS, recognizing 100+ languages and deploying segments in 30+. Grapeshot is integrated with all major programmatic trading marketplaces including AppNexus, MediaMath, Turn, The Trade Desk, AdForm, iPinYou and AOL. The core technology is also available through an API. Grapeshot has offices located in Cambridge, London, New York, Chicago, San Francisco, Singapore and Sydney.
News Article | February 15, 2017
QPS Employment Group, a staffing and recruiting agency, started 31 years ago in the basement of its president’s home in Wisconsin. It has expanded throughout the Midwest with over 50 branches, including Fort Dodge, where it has had an office for four years. The company now employs more than 300 internal employees, and just last year successfully hired almost 5,000 people into permanent positions. In fact, it boasts a 97 percent success rate in placing professionals in some of the most sought-after positions with companies, and 95 percent of placements stay over a year. “We’re a Midwest company that is family-oriented, and brings together the expertise and resources of a large national firm with the personalized attention to detail and in-depth market knowledge that you typically get from a small, local agency,” says Amy Berding, account executive for Fort Dodge. QPS maintains the philosophy that the right job has the power to change lives. It has helped thousands of companies improve their workforce and bottom line since its founding in 1985. QPS staffs for accounting, engineering, information technology, manufacturing management, sales, and human resources positions alike. In Fort Dodge, the company is looking to fill positions such as maintenance technicians, automation engineers, production supervisors, CNC operators, assembly workers, and many more. Additional information on these positions is available at the QPS Employment Group Fort Dodge office located at 1426 Central Ave, Ste A., email address is FortDodge(at)qpsemployment(dot)com or call 515-955-5575. #ThisIsFortDodge is a community branding campaign available on ThisIsFortDodge.com, Facebook, Twitter, Google+, YouTube, SnapChat and Instagram. Information is available at spinmarkket.com or by calling 515-302-8026. KCCI who was a partner in producing this sponsored content, is located at 888 9th Street, Des Moines, IA 50309.
News Article | December 5, 2016
Global Contract Research Organization (CRO) Market for Early-Stage Development Services and Last-Stage Development Services: Global Industry Perspective, Comprehensive Analysis and Forecast 2014 – 2020 The report covers forecast and analysis for the contract research organization (CRO) market on a global and regional level. The study provides historic data of 2014 along with a forecast from 2015 to 2020 based on revenue (USD billion). The study includes drivers and restraints for the contract research organization market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the contract research organization market on a global level. In order to give the users of this report a comprehensive view on the contract research organization market, we have included a detailed buying criteria, product portfolio, competitive scenario, and analysis of key industry players. To understand the competitive landscape in the market, an analysis of Porter’s Five Forces model for the contract research organization market has also been included. The study encompasses a market attractiveness analysis, wherein product segments are benchmarked based on their market size, growth rate and general attractiveness. The study provides a decisive view on the contract research organization market by segmenting the market based on applications. All the end-user segments have been analyzed based on present and future trends and the market is estimated from 2014 to 2020. Key end-user market covered under this study include early-stage development services and last-stage development services. The regional segmentation includes the current and forecast demand for Americas, EMEA (Europe, Middle East & Africa) and Asia Pacific with its further bifurcation into major countries including U.S., China, and India. This segmentation includes demand for contract research organization market based on individual applications in all the regions and countries. This Report covered some of the key players involved globally in contract research organization market includes Covance, Parexel International, PRA Health Sciences, Quintiles Translational. Other prominent players in the contract research organization market includes Chiltern, Charles River Laboratories, Icon, Inventiv Health, QPS, Ricerca Biosciences, EPS , SynteractHCR, INC Research, WIL Research and WuXi AppTec.
News Article | November 4, 2016
Zion Research has published a new report titled “Contract Research Organization (CRO) Industry for Early-Stage Development Services and Last-Stage Development Services: Global Market Perspective, Comprehensive Analysis and Forecast, 2014 - 2020.” According to the report, global Contract Research Organization market was valued at USD 34.00 billion in 2014 and is expected to reach USD 59.42 billion in 2020, growing at a CAGR of 9.80% between 2015 and 2020. CRO is the organization that supports outsourced research and development services for the various industries like pharmaceutical, biotechnology, medical devices industries, government institutions, foundations, and universities. The demand for contract research organizations has been fuelled by advanced clinical development programs and the demand for new pharmaceutical products across the globe. The research and development of pharmaceutical products typically needs around 15 years. In order to lower down the expenditure research and development and cut down the time required for product marketing, and focus on other operational activities, pharmaceutical vendors are outsourcing preclinical and other drug development phases to CROs. Moreover, the high failure rate of clinical trials is also expected to trigger the demand for CROs by pharmaceutical and biopharmaceutical vendors to outsource their R&D. Global CRO industry has witnessed the rise in strategic alliances, acquisitions, and joint ventures among vendors in the CRO market. These strategic initiatives are intended at extending service offerings and geographical presence across the world. Pharmaceutical manufacturing companies in emerging countries in Asia Pacific, Latin America and Eastern Europe account for the majority of outsourcing activities owing to easy access to large pools of treatment naïve patients, low labor and manufacturing costs, and a skilled medical workforce. The contract research organization market is segmented on the basis of the end-user segmentation which includes early-stage development services and last-stage development services. The late-stage development services segment includes phase II-IV clinical trials and central laboratory services. The last-stage development services was the largest end-user segment for the CRO market and accounted for over 70% share of the total market in 2014. Last-stage development services segment is also expected to exhibit fastest growth rate during the years to come. The contract research organization market is segmented on the basis of the regions such as Americas, EMEA (Europe, Middle East and Africa) and APAC (Asia Pacific). The Americas dominated the global CRO market with around 50% share of the total market in 2014. CRO market in Americas is led by U.S. Some of the key players involved globally in contract research organization market include Covance, Parexel International, PRA Health Sciences, Quintiles Translational. Other major players in the contract research organization market includes Chiltern, Charles River Laboratories, Icon, Inventiv Health, QPS, Ricerca Biosciences, EPS , SynteractHCR, INC Research, WIL Research and WuXi AppTec.
News Article | November 16, 2016
Amyloid-beta (Abeta) aggregate-clearing by the murine anti-pyroglutamate-3 Abeta IgG2a monoclonal antibody PBD-C06 with and without a complement mutation in an Alzheimer's mouse model HALLE (SAALE), Germany, 16 November 2016 - Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer's disease (AD), announced today the first results of a preclinical study in an AD mouse model with the pyroglutamate-3 Abeta (pGlu3-Abeta)-specific antibody mPBD-C06, comparing versions with and without a mutation eliminating complement activation which will be presented as a poster at the Society for Neuroscience (SfN) meeting on 16 November 2016 in San Diego, CA. Data were generated in collaboration with Cynthia Lemere of Brigham and Women's Hospital, Harvard Medical School, and QPS, Graz, Austria. Previously, Lemere's team showed that the mouse IgG2a variant of the anti-pGlu3-Abeta monoclonal antibody was more effective at clearing Abeta aggregates and rescued behavioral deficits compared to the mouse IgG1 version (SfN 2015). In the present study, the effect of eliminating the antibody's ability to activate complement (CDC) on the efficiency to reduce Abeta plaques was investigated and it was found that both variants - with and without CDC - reduced pGlu3-Abeta as well as general Abeta to the same extent - without inducing microhemorrhages. Thus, avoiding complement activation did not impact the capacity of mPBD-C06 to eliminate pGlu3-Abeta aggregates. In addition, microglial activation was assessed in vivo by 18F-GE180 TSPO microPET imaging at baseline and following a single injection of the pGlu3-Abeta antibody variants. In contrast to the IgG2a variant, which showed enhanced whole brain uptake of 18F-GE180 in AD mice, the antibody lacking CDC did not alter the TSPO signal after injection. In summary, the data demonstrate for the first time, that microglial activation, analyzed by TSPO microPET, can be reduced by CDC inactivation without impairing the potency of the antibody to clear amyloid deposits. Further studies are underway to better understand the clearance mechanisms for each of these anti-pGlu3 Abeta antibodies. Inge Lues, Chief Development Officer of Probiodrug, commented: "These data are very exciting as they demonstrate efficient Abeta clearance without potential side- or dose-limiting effects of inducing inflammation." Cynthia Lemere, PhD, scientist at Brigham and Women's Hospital, added: "Although further investigation is needed, these early data suggest that the novel CDC-mutant anti-pGlu3 Abeta antibody may improve efficacy and safety as an AD immunotherapy." Lemere is currently the recipient of pre-clinical sponsored research from Probiodrug AG. For more information please contact: About Probiodrug AG Headquartered in Halle (Saale), Germany, Probiodrug AG (Euronext Amsterdam: PBD) is a biopharmaceutical company focused on the development of new therapeutic products for the treatment of Alzheimer's disease. Founded in 1997, the company successfully developed a novel therapeutic concept for diabetes - the DP4 inhibitors - which provided the basis for a novel class of antidiabetics - the gliptins. Its core capabilities are based on its long-standing expertise in the elucidation of the structure and function of enzymes involved in the modification of proteins and peptides, which play a central role in pathological conditions. Today Probiodrug's aim is to become a leading company in the development of Alzheimer's disease treatments and to thereby provide a better life for Alzheimer's disease patients. It has identified a new therapeutic concept linked to disease initiation and progression. The development approaches are targeting pyroglutamate-Abeta (pGlu-Abeta) as a therapeutic strategy to fight Alzheimer's disease. The Company has medical use and composition of matter patents related to the inhibition of Glutaminyl Cyclase (QC) and anti-pGlu-Abeta- specific monoclonal antibodies, providing it, in the Company's view, with a leading position in this field of research. Probiodrug's lead product candidate, PQ912, is a highly specific and potent inhibitor of Glutaminyl Cyclase (QC), which has shown therapeutic effects in Alzheimer's animal models. PQ912 is currently in a Phase 2a study, the SAPHIR trial. In a preceding Phase 1 study with healthy young and elderly volunteers, PQ912 has shown to be safe and well tolerated and also revealed high QC-inhibition. www.probiodrug.de About Alzheimer's disease Alzheimer's disease is a neurological disorder, which is the most common form of dementia, and ultimately leads to death. Because Alzheimer's disease cannot be cured and is degenerative, the affected patients must increasingly rely on others for assistance. . Today, 47 million people live with dementia worldwide, and this number is projected to treble to more than 131 million by 2050, as populations age. Dementia also has a huge economic impact. Alzheimer's also has an estimated, global societal cost of US$ 818 billion, and it will become a trillion dollar disease by 2018. (World Alzheimer Report 2016). Forward Looking Statements Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgment of Probiodrug AG as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.
News Article | February 23, 2017
PARIS--(BUSINESS WIRE)--Acticor Biotech, a biotechnology company focused on the treatment of acute ischemic stroke, today announced that it selected its CRO (Contract Research Organization) to manage its clinical study phase I. The first-in-human study with ACT017 will be conducted at QPS facilities in Groningen, the Netherlands. QPS is a GLP/GCP-compliant contract research organization supporting discovery, preclinical and clinical drug development. The submission is planned for September 2017 and the first cohort of volunteers is planned for October 2017. The clinical study will enrol 48 subjects in 6 escalating dose level cohorts, with each cohort consisting of 8 subjects: 6 on active and 2 on placebo at the following planned doses: 100, 250, 500, 750, 1,000 and 2,000 mg. The goal is to assess safety and tolerance as well as parameters of haemostasis and coagulation and to determine pharmacokinetic and pharmacodynamics parameters.
News Article | November 11, 2016
The ever-increasing threat of terrorist attacks means screening technologies that are more advanced than common metal detectors are required at security checkpoints. Current imaging systems—working in the millimeter wave (mmW) range—have been proven to offer good results in the detection of metallic and non-metallic threats (e.g., explosives, ceramic knives, or self-made bomb precursors). During the screening process for these systems, however, passengers (i.e., at airports) must adopt a specific position and posture,1–3 or they must move in a specific way in front of the scanner.4 Furthermore, it is desirable for future screening systems to simultaneously offer a higher throughput and detection performance. High throughput and detection performance can both be achieved with a so-called walk-through system (WTS), which is used to screen a person as they pass the scanner. On one hand, this setup is more pleasant for passengers because no specific posture has to be adopted (which also means queues can be avoided in most cases). On the other hand, however, the detection performance of such systems could be enhanced. This is because a number of different snapshots, from different angles of view, are required to realize the full illumination necessary to scan a person. Each part of the body therefore has to be screened at least once. If a WTS were also to offer a high frame rate, tracking of potential threats would thus be possible (i.e., by improving the detection rate and reducing the number of false alarms). In our work,5 we have investigated the concept of a WTS that is based on an already-existing fully electronic mmW scanner.3 This device, which does not include any moving mechanical parts, is known as the Quick Personnel Security (QPS) scanner and is shown in Figure 1(a). The QPS system, which works across a frequency range of 70–80GHz, consists of 3008 transmit and 3008 receive antennas that are distributed over an aperture of 1 × 2m. This large aperture, and the 75GHz center frequency, mean that the system has a high spatial resolution (2 × 2 × 10mm). Data acquisition with the QPS takes less than 20ms,1 and 3D images with optimum spatial resolution are generated through digital focusing (which is implemented with field programmable gate arrays). More detailed descriptions of the system have previously been published.1, 6 A sketch of our proposed WTS concept is shown in Figure 1(b). The basis for our design is to synchronize both panels of the existing scanner system and to reuse the mmW components to achieve a real-time imaging capability. Our scanner would be of great benefit to airports since currently installed systems can be updated to the WTS version, without requiring any change in the layout of the security lanes. For screening with our WTS, the passenger walks between the two synchronized panels and three snapshot measurements are acquired (see Figure 2). From these three snapshots we obtain scans of the person's front, sides, and back. This is the minimum number of snapshots that are required to provide full-body illumination (as verified by the ray-tracing simulations shown in Figure 3). Some areas of the body (shown in green) are illuminated by transmission measurements from both scanners, whereas other areas (blue or yellow) are illuminated by separate reflection measurements from each scanner. We have also demonstrated the expected imaging capability of our scanner by using an experimental system (see Figure 4). Our experimental apparatus consists of two synchronized antenna arrays that are separated by a distance of 1.5m. Each array contains 1504 transmit and receive antennas, distributed over an area of 1m2. The image quality we can obtain through the first/third snapshots is illustrated in Figure 5(a). In this scan a hidden ceramic knife on the back of a person is clearly visible. In addition, we show the scan result from the second snapshot in Figure 5(b). In this case, the person was hiding a surrogate for an explosive on their left side, which can be seen in the image. Our successful experimental results therefore verify the potential of our full-body illumination approach. Indeed, when a passenger adopts the optimal posture, this full-body illumination could lead to increased detection rates. In addition, multiple imaging frames could be obtained when people are scanned in arbitrary postures to compensate for shadowing of extremities. This would also allow potential threats to be tracked through several frames. In summary, we have investigated a new walk-through scanning system concept for security applications. Our WTS is based on existing millimeter-wave technology and consists of two synchronized arrays of transmit/receive antennas. We have demonstrated that three snapshots is the minimum number required to achieve full-body illumination. We have also conducted an experimental demonstration of our system to illustrate its imaging capabilities. Our proposed system has several benefits, including the reuse of current mmW technology. It should also be possible to implement our WTS by simply updating currently installed scanners. In addition, the full-body illumination of our approach means that we can realize better detection performance, with less annoyance to passengers. In the next step of our work we will investigate the visibility of several objects fixed to different parts of the human body. For these tests, we will use two synchronized panels in our system.